Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

1.550 -0.070 (-4.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Bull Of The Day: Crispr Therapeutics
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
1 Promising Stock Down 66% That Could Skyrocket in 2024
Financial results aren't what matters most right now for this company. 
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace
A Preview Of Editas Medicine's Earnings
Via Benzinga
Analyst Ratings for Editas Medicine
Via Benzinga
Is Editas Stock a Buy Now?
Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now? 
Via The Motley Fool
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
Investors may want to strongly consider this new list of stocks to buy that could double in 2024. Check out these hidden gems. 
Via InvestorPlace
The 3 Best Gene Editing Stocks on the Frontier of Medicine
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. 
Via InvestorPlace
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
3 Long-Term Growth Stocks Analysts Are Bullish On
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two. 
Via InvestorPlace
3 Biotech Stocks That Are Betting on the Future of Gene Editing
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For November 3, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Via Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
Both are in a race against time to commercialize a medicine before cash runs out. 
Via The Motley Fool
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
It's key to understand the resources it will take to deliver a company's pipeline. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.